Lexaria’s Technology Beats Baseline by 499% in Lab Study

Lexaria, Corp. (LXRP) (CNSX:LXX) (the “Company”) is very pleased to announce potential industry-changing achievements in enhanced gastro-intestinal absorption of cannabidiol (CBD) utilizing Lexaria’s patent pending technology. The recent third-party testing was conducted in two phases of in vitro tests beginning in June and completed in August, 2015. The independent laboratory results have delivered average CBD…

The post Lexaria’s Technology Beats Baseline by 499% in Lab Study appeared first on Marijuana Index.